Silicon Valley Bank shutters; Rare disease trials can't find enough patients; FDA adcomm votes in favor of Polivy label expansion; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
As a reminder, we’re collecting nominations for our annual 20 under 40 and LGBTQ+ features. The deadlines are March 23 and March 16, respectively, so be sure to submit your nominations!
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.